Skip to content

TLC-ART Concepts

TLC-ART’s Platform technology intends to provide a single long-acting injection containing appropriate drug combinations targeted to HIV host cells and tissues to provide sustained exposures.  Consistent drug exposures in HIV host cells in the tissues that harbor residual viruses may overcome drug insufficiency often experienced by patients taking daily oral medications.

We plan to test the hypothesis that overcoming drug insufficiency and limiting sustained tissue exposures could lead to a functional cure with the help of immune recovery of HIV patients on cART.  For additional detail please see the following list of published concept review articles.

Highlight Articles

A novel formulation enabled transformation of 3-HIV drugs tenofovir–lamivudine–dolutegravir from short-acting to long-acting all-in-one injectable. AIDS, 2023

Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101. J Pharm Sci, 2020

Drug Targeting in Nanomedicine and NanoPharmacy: A Systems Approach. In Nanopharmacy: Nanotechnology-Based Production of Pharmaceuticals, Ho RJY, McConnachie and L., Shao J. 2016. Wiley-VH Verlag GmbH & Co. KGaA, Weinheim, Germany.

Translation of Combination Nanodrugs into Nanomedicines: Lessons Learned and Future. Mu Q, Yu J, McConnachie LA, Kraft JC, Gao Y, Gulati GK and Ho RJY. 2017. Outlook. J. Drug Target Dec 29: 1-31.

Systems Approach to targeted and long-acting HIV/AIDS therapy. Ho RJY, Yu J, Li B, Kraft JC, Freeling JP, Koehn J, Shao J. 2015. Drug Deliv Transl Res. 5(6):531-9.

Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS. Shao J, Kraft JC, Li B, Yu J, Freeling J, Koehn J, Ho RJY. 2016. Nanomedicine (Lond). 11(5):545-564.